Biogen (BIIB) Expected to Announce Earnings on Thursday

Biogen (NASDAQ:BIIB - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Biogen to post earnings of $3.59 per share and revenue of $2.25 billion for the quarter. Biogen has set its FY 2025 guidance at 15.250-16.250 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping analysts' consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. On average, analysts expect Biogen to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Biogen Stock Down 0.6 %

NASDAQ:BIIB traded down $0.67 during mid-day trading on Friday, hitting $118.84. The stock had a trading volume of 1,538,299 shares, compared to its average volume of 1,350,289. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. Biogen has a twelve month low of $110.04 and a twelve month high of $238.00. The company has a market capitalization of $17.40 billion, a PE ratio of 10.62, a PEG ratio of 1.51 and a beta of 0.06. The stock has a 50-day simple moving average of $132.47 and a two-hundred day simple moving average of $149.39.

Insider Activity

In other news, Director Stephen A. Sherwin sold 8,760 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares of the company's stock, valued at $1,697,926.36. This trade represents a 43.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

BIIB has been the topic of a number of analyst reports. Wells Fargo & Company cut their price target on Biogen from $165.00 to $140.00 and set an "equal weight" rating on the stock in a research note on Thursday, February 13th. Truist Financial decreased their target price on Biogen from $220.00 to $210.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Needham & Company LLC reiterated a "hold" rating on shares of Biogen in a research note on Friday. The Goldman Sachs Group reduced their price objective on shares of Biogen from $219.00 to $197.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Morgan Stanley dropped their target price on shares of Biogen from $157.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Eighteen research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $211.37.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.